Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGM2 | P21980 | 1/20 | 0.66 |
| ▸ | GAA | P10253 | 1/20 | 0.61 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 3/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.54 |
| ▸ | IDO1 | P14902 | 1/20 | 0.53 |
| ▸ | MAOB | P27338 | 3/20 | 0.53 |
| ▸ | HPGD | P15428 | 2/20 | 0.53 |
| ▸ | MAOA | P21397 | 2/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | GRM5 | P41594 | 1/20 | 0.50 |
| ▸ | GRK2 | P25098 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19707566 | 0.83 | GAA (0.65) | TGM2GAAP2RX1MEN1KMT2A | |
| SCHEMBL1400845 | 0.82 | GAA (0.62) | TGM2GAAP2RX1MEN1KMT2A | |
| SCHEMBL2090960 | 0.82 | GAA (0.62) | TGM2GAAP2RX1MEN1KMT2A | |
| SCHEMBL28641144 | 0.81 | ALDH1A1 (0.61) | TGM2GAAP2RX1MEN1KMT2A | |
| SCHEMBL5142687 | 0.80 | GAA (0.77) | TGM2GAAP2RX1MEN1KMT2A | |
| SCHEMBL264735 | 0.80 | GAA (0.66) | TGM2GAAP2RX1ALDH1A1RAB9A | |
| SCHEMBL167814 | 0.80 | GAA (0.61) | TGM2GAAP2RX1MEN1KMT2A | |
| SCHEMBL31598559 | 0.79 | TGM2 (0.60) | TGM2GAAP2RX1MEN1KMT2A | |
| SCHEMBL515153 | 0.79 | TGM2 (0.60) | TGM2GAAP2RX1MEN1KMT2A | |
| SCHEMBL1381249 | 0.79 | TGM2 (1.00) | TGM2GAALMNAMAOBMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1885717-B1 | SHP-2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS COMPRISING THEM AND THEIR USE FOR TREATING PHOSPHATASE-MEDIATED DISEASES | MAX DELBRUECK CENTRUM (DE) | 2011-08-17 | — | — | EP | claimed |
| US-20080194563-A1 | Shp-2 Inhibitors, Pharmaceutical Compositons Comprising Them and Their Use For Treating Phosphatase-Mediated Diseases | MAX-DELBRUCK-CENTRUM FUR MOLEKULARE MEDIZIN (DE) | 2008-08-14 | — | — | US | claimed |
| EP-1885717-A1 | SHP-2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS COMPRISING THEM AND THEIR USE FOR TREATING PHOSPHATASE-MEDIATED DISEASES | MAX-DELBRÜCK-CENTRUM FÜR MOLEKULARE MEDIZIN (DE) | 2008-02-13 | — | — | EP | claimed |
| WO-2006128909-A1 | SHP-2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS COMPRISING THEM AND THEIR USE FOR TREATING PHOSPHATASE-MEDIATED DISEASES | Max-Delbrück-Centrum für Molekulare Medizin (DE) | 2006-12-07 | — | — | WO | claimed |
| EP-1885717-B1 | SHP-2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS COMPRISING THEM AND THEIR USE FOR TREATING PHOSPHATASE-MEDIATED DISEASES | MAX DELBRUECK CENTRUM (DE) | 2011-08-17 | — | — | EP | disclosed |
| US-7868185-B2 | Shp-2 inhibitors and pharmaceutical compositions comprising them | MAX-DELBRUCK-CENTRUM FUR MOLEKULARE MEDIZIN (DE) | 2011-01-11 | — | — | US | disclosed |
| US-20080194563-A1 | Shp-2 Inhibitors, Pharmaceutical Compositons Comprising Them and Their Use For Treating Phosphatase-Mediated Diseases | MAX-DELBRUCK-CENTRUM FUR MOLEKULARE MEDIZIN (DE) | 2008-08-14 | — | — | US | disclosed |
| EP-1885717-A1 | SHP-2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS COMPRISING THEM AND THEIR USE FOR TREATING PHOSPHATASE-MEDIATED DISEASES | MAX-DELBRÜCK-CENTRUM FÜR MOLEKULARE MEDIZIN (DE) | 2008-02-13 | — | — | EP | disclosed |
| WO-2006128909-A1 | SHP-2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS COMPRISING THEM AND THEIR USE FOR TREATING PHOSPHATASE-MEDIATED DISEASES | Max-Delbrück-Centrum für Molekulare Medizin (DE) | 2006-12-07 | — | — | WO | disclosed |
| EP-1728790-A1 | Shp-2 inhibitors, pharmaceutical compositions comprising them and their use for treating phosphatase-mediated diseases | MAX-DELBRÜCK-CENTRUM FÜR MOLEKULARE MEDIZIN (DE) | 2006-12-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194563-A1 | Shp-2 Inhibitors, Pharmaceutical Compositons Comprising Them and Their Use For Treating Phosphatase-Mediated Diseases | PTPN2, PTPRJ, PTPRS | TGM2 1040/4885GAA 2316/4885P2RX1 1364/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.